glp 1 and ibd A schematic representation of the mechanism of glucagon-like peptide-1 OBESITY AND IBD by @EdwardLoftus2

Lebrun LJ, Lenaerts K, Kiers D, Pais de Barros JP, Le Guern N, Plesnik J, et al

When it comes to off-label prescribing, many specialist physicians report that they have seen benefits

This distinction alone fundamentally changes the treatment calculus, because chronic conditions typically require chronic treatment, and obesity is a chronic condition

However, we argue that lacking adjustment of these factors will not bias our results because these factors might act as mediators instead of confounding factors based on the available evidence that poor glucose control will lead to DR, whereas using GLP-1 RAs will help to control glucose control

Delaying gastric emptying: slowing digestion, which helps to reduce hunger